Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has announced a General Meeting scheduled for June 11, 2025, at their Cardiff offices. The company is proposing four key resolutions: (1) subdivision of each issued ordinary share of £0.001 into one ordinary share of £0.00005 and 19 C deferred shares of £0.00005, (2) authorization for Directors to allot shares up to £476,954.10 nominal value until 2028 AGM, (3) empowerment of Directors to allot equity securities for cash without pre-emption rights, and (4) adoption of new articles of association.
The primary purpose of these resolutions is to lower the par value of ordinary shares and enable the company to issue shares above par value. Importantly, the company states that these changes will not affect the number of outstanding ordinary shares or American Depositary Shares.
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) ha annunciato un'Assemblea Generale prevista per l'11 giugno 2025 presso i loro uffici di Cardiff. La società propone quattro delibere principali: (1) la suddivisione di ogni azione ordinaria emessa da £0,001 in un'azione ordinaria da £0,00005 e 19 azioni differite C da £0,00005, (2) l'autorizzazione ai Direttori di assegnare azioni fino a un valore nominale di £476.954,10 fino all'Assemblea Generale del 2028, (3) il potere ai Direttori di assegnare titoli azionari in contanti senza diritti di prelazione, e (4) l'adozione di nuovi articoli di associazione.
Lo scopo principale di queste delibere è ridurre il valore nominale delle azioni ordinarie e consentire alla società di emettere azioni sopra il valore nominale. È importante sottolineare che la società afferma che questi cambiamenti non influiranno sul numero di azioni ordinarie in circolazione né sulle American Depositary Shares.
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) ha anunciado una Junta General programada para el 11 de junio de 2025 en sus oficinas de Cardiff. La compañía propone cuatro resoluciones clave: (1) subdividir cada acción ordinaria emitida de £0,001 en una acción ordinaria de £0,00005 y 19 acciones diferidas C de £0,00005, (2) autorización para que los Directores asignen acciones hasta un valor nominal de £476,954.10 hasta la Junta General de 2028, (3) facultad para que los Directores asignen valores de capital en efectivo sin derechos de preferencia, y (4) adopción de nuevos estatutos sociales.
El propósito principal de estas resoluciones es reducir el valor nominal de las acciones ordinarias y permitir que la empresa emita acciones por encima del valor nominal. Es importante destacar que la compañía afirma que estos cambios no afectarán el número de acciones ordinarias en circulación ni las American Depositary Shares.
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX)는 2025년 6월 11일 카디프 사무실에서 정기총회를 개최할 예정이라고 발표했습니다. 회사는 네 가지 주요 결의안을 제안합니다: (1) 발행된 보통주 £0.001를 £0.00005 보통주 1주와 £0.00005의 C 이연주 19주로 분할, (2) 2028년 정기총회까지 명목가치 £476,954.10까지 주식 할당 권한 부여, (3) 우선매수권 없이 현금으로 자본 증권 할당 권한 부여, (4) 새로운 정관 채택.
이 결의안들의 주요 목적은 보통주의 액면가를 낮추고 회사가 액면가 이상의 주식을 발행할 수 있도록 하는 것입니다. 회사는 이러한 변경이 발행된 보통주 수나 미국 예탁증서 수에 영향을 미치지 않을 것임을 명확히 밝혔습니다.
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) a annoncé une Assemblée Générale prévue le 11 juin 2025 dans leurs bureaux de Cardiff. La société propose quatre résolutions principales : (1) la subdivision de chaque action ordinaire émise de £0,001 en une action ordinaire de £0,00005 et 19 actions différées C de £0,00005, (2) l'autorisation pour les administrateurs d'attribuer des actions jusqu'à une valeur nominale de £476 954,10 jusqu'à l'Assemblée Générale de 2028, (3) le pouvoir donné aux administrateurs d'attribuer des titres de capital contre espèces sans droits préférentiels, et (4) l'adoption de nouveaux statuts.
L'objectif principal de ces résolutions est de réduire la valeur nominale des actions ordinaires et de permettre à la société d'émettre des actions au-dessus de leur valeur nominale. Il est important de noter que la société affirme que ces changements n'affecteront ni le nombre d'actions ordinaires en circulation ni les American Depositary Shares.
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) hat eine Hauptversammlung für den 11. Juni 2025 in ihren Büros in Cardiff angekündigt. Das Unternehmen schlägt vier wesentliche Beschlüsse vor: (1) die Aufteilung jeder ausgegebenen Stammaktie im Nennwert von £0,001 in eine Stammaktie im Nennwert von £0,00005 und 19 C-Vorzugsaktien im Nennwert von £0,00005, (2) die Ermächtigung der Direktoren zur Ausgabe von Aktien bis zu einem Nennwert von £476.954,10 bis zur Hauptversammlung 2028, (3) die Befugnis der Direktoren, Eigenkapitalwerte gegen Barzahlung ohne Bezugsrechte auszugeben, und (4) die Annahme neuer Satzungsbestimmungen.
Der Hauptzweck dieser Beschlüsse besteht darin, den Nennwert der Stammaktien zu senken und dem Unternehmen zu ermöglichen, Aktien über dem Nennwert auszugeben. Wichtig ist, dass das Unternehmen angibt, dass diese Änderungen weder die Anzahl der ausstehenden Stammaktien noch die American Depositary Shares beeinflussen werden.
- None.
- None.
May 22, 2025
Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)
Notice of General Meeting
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company’s offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 11 June 2025 at 1.00pm was posted to shareholders today.
The Board of Directors is proposing four resolutions:
Ordinary Resolutions
1. That, subject to and conditional on the passing of Resolution 4, each of the issued ordinary shares of
2. That the Directors of the Company be generally and unconditionally authorised in accordance with Section 551 of the Companies Act 2006 (the “Act”), in addition to any existing authorities to allot equity securities to the extent unused, to exercise all powers of the Company to allot shares in the Company or to grant rights to subscribe for or convert any security into shares in the Company up to an aggregate nominal value of
Special Resolutions
3. That, subject to and conditional upon the passing of Resolution 2, the Directors of the Company be and hereby generally empowered pursuant to Sections 570 of the Act to allot equity securities (within the meaning of Section 560 of the Act) wholly for cash, in addition to any existing authorities to allot equity securities to the extent unused, pursuant to the authority conferred by Resolution 2 as set out in this Notice, as if Section 561 of the Act did not apply to such allotment, provided that this power shall expire at the conclusion of the Annual General Meeting of the Company to be held in 2028.
4. That, subject to and conditional on the passing of Resolution 1, the draft articles of association tabled at the meeting, initialled by the Chairman, and available on the Company’s website, www.biodexapharma.com and labelled the ‘New Articles’, be approved and adopted as the new articles of association of the Company in substitution for and to the entire exclusion of the Company’s existing articles of association.
The purpose of the Resolutions is to lower the par value of the ordinary shares and allow the Company to issue ordinary shares above par value.
Neither the number of ordinary shares outstanding nor the number of American Depositary Shares will change as a result of passing of the Resolutions.
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.
| Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising. |
FAQ
When is Biodexa Pharmaceuticals (BDRX) General Meeting scheduled for 2025?
What are the main resolutions proposed at Biodexa's (BDRX) 2025 General Meeting?
Will BDRX's share subdivision affect the number of outstanding shares?
What is the purpose of Biodexa's (BDRX) proposed share subdivision in 2025?
What is the nominal value limit for share allotment in BDRX's 2025 resolution?
